WALTHAM, Mass., May 12, 2026
Definium Therapeutics announced that the first patient has been dosed in the pivotal ASCEND Phase 3 clinical trial evaluating DT120-ODT for the treatment of major depressive disorder (MDD), marking a major milestone for the company’s late-stage neuroscience pipeline. The ASCEND study represents the second Phase 3 pivotal trial for DT120-ODT, an investigational sublingual orally disintegrating tablet formulation of dexmedetomidine, designed to provide rapid relief of depressive symptoms in adults with major depressive disorder. The initiation of dosing follows encouraging results from previous mid-stage and late-stage studies that demonstrated rapid antidepressant effects, favorable tolerability, and the potential to address critical unmet needs in psychiatric care. With depression rates continuing to rise globally and treatment-resistant symptoms affecting millions of patients, the advancement of DT120-ODT positions Definium Therapeutics within the growing market for fast-acting neuropsychiatric therapies.
ASCEND Trial Expands Development of Rapid-Acting Depression Therapy
According to Definium Therapeutics, the randomized, double-blind, placebo-controlled ASCEND Phase 3 study will evaluate the efficacy, safety, and tolerability of DT120-ODT in adults diagnosed with major depressive disorder. The company stated that the investigational therapy is specifically designed to provide a rapid onset of antidepressant activity while avoiding many of the administration challenges associated with existing fast-acting depression treatments. DT120-ODT uses a sublingual orally disintegrating tablet platform that enables convenient dosing without intravenous infusion or intranasal device administration, potentially improving accessibility and patient adherence in outpatient psychiatric settings.
Definium emphasized that the clinical development program is focused on addressing significant limitations associated with currently available antidepressants, many of which require several weeks before symptom improvement becomes noticeable. The company believes DT120-ODT may provide a differentiated treatment approach capable of producing faster clinical response in patients experiencing severe depressive episodes. Major depressive disorder remains one of the world’s most prevalent mental health conditions, contributing substantially to disability, reduced productivity, and increased suicide risk globally. Industry analysts estimate that more than 280 million people worldwide are affected by depression, reinforcing the urgent need for therapies capable of delivering rapid and sustained symptom relief.
The ASCEND study follows earlier clinical data demonstrating statistically significant reductions in depressive symptoms as measured by standardized psychiatric assessment scales. Definium previously reported that patients receiving DT120-ODT experienced meaningful symptom improvement within hours after dosing, supporting the therapy’s potential role as a rapid-acting antidepressant candidate. Researchers also observed a manageable safety profile during prior studies, with sedation, dizziness, and transient blood pressure changes among the commonly reported treatment-emergent adverse events. The company stated that safety monitoring and cardiovascular assessments will remain important components of the ongoing Phase 3 program as development advances toward potential regulatory submission.
Advertisement
Definium Expands Position in Neuroscience and Psychiatry Market
The initiation of the second pivotal Phase 3 trial reflects Definium Therapeutics’ broader strategy to strengthen its position in the expanding neuroscience and psychiatric therapeutics market. Rapid-acting antidepressants have become a major area of pharmaceutical investment following growing recognition that traditional selective serotonin reuptake inhibitors (SSRIs) often fail to provide adequate or timely relief for many patients. Over the past several years, the psychiatric treatment landscape has increasingly shifted toward novel mechanisms capable of targeting severe depression, suicidal ideation, and treatment-resistant symptoms with improved speed and efficacy.
DT120-ODT is based on dexmedetomidine, an alpha-2 adrenergic receptor agonist with established pharmacologic activity that Definium has reformulated into a proprietary orally disintegrating tablet for psychiatric applications. The company believes its differentiated delivery platform may provide important advantages compared with infusion-based therapies by supporting simplified administration and broader clinical adoption. Mental health specialists have noted that patient-friendly formulations are becoming increasingly important as healthcare systems seek scalable solutions for managing rising depression prevalence and psychiatric treatment demand.
The global depression therapeutics market continues to attract significant investment as pharmaceutical companies pursue next-generation neuropsychiatric medicines targeting faster response times and improved patient outcomes. Analysts expect rapid-acting antidepressants, neuroplasticity-focused therapies, and novel receptor-targeting compounds to remain among the most competitive segments in CNS drug development over the next decade. Definium executives stated that initiation of the ASCEND study marks an important step toward potentially delivering a new treatment option for patients living with major depressive disorder while advancing the company’s broader neuroscience innovation strategy.
Source: Definium Therapeutics press release
